RT Journal Article
SR Electronic
T1 Post-acute COVID-19 associated with evidence of bystander T-cell activation and a recurring antibiotic-resistant bacterial pneumonia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.17.20190033
DO 10.1101/2020.09.17.20190033
A1 Michaela Gregorova
A1 Daniel Morse
A1 Tarcisio Brignoli
A1 Joseph Steventon
A1 Fergus Hamilton
A1 Mahableshwar Albur
A1 David Arnold
A1 Matthew Thomas
A1 Alice Halliday
A1 Holly Baum
A1 Christopher Rice
A1 Matthew B. Avison
A1 Andrew D. Davidson
A1 Marianna Santopaolo
A1 Elizabeth Oliver
A1 Anu Goenka
A1 Adam Finn
A1 Linda Wooldridge
A1 Borko Amulic
A1 Rosemary J. Boyton
A1 Daniel M. Altmann
A1 David K. Butler
A1 Claire McMurray
A1 Joanne Stockton
A1 Sam Nicholls
A1 Charles Cooper
A1 Nicholas Loman
A1 Michael J. Cox
A1 Laura Rivino
A1 Ruth C. Massey
YR 2020
UL http://medrxiv.org/content/early/2020/09/22/2020.09.17.20190033.abstract
AB Here we describe the case of a COVID-19 patient who developed recurring ventilator-associated pneumonia caused by Pseudomonas aeruginosa that acquired increasing levels of antimicrobial resistance (AMR) in response to treatment. Metagenomic analysis revealed the AMR genotype, while immunological analysis revealed massive and escalating levels of T-cell activation. These were both SARS-CoV-2 and P. aeruginosa specific, and bystander activated, which may have contributed to this patient’s persistent symptoms and radiological changes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSouthmead Hospital Charity (Registered Charity Number: 1055900) Wellcome Trust (reference number: 212258/Z/18/Z) Elizabeth Blackwell Institute, University of Bristol Cystic Fibrosis Trust PhD studentship (CF Trust SRC 015). UKRI (MR/S019553/1 & MR/R02622X/1) Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval via South Yorkshire REC: 20/YH/0121, CRN approval no: 45469 NHS Research Ethics Committee approval ref 14/WA/1253All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is freely available